Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) complicated with sarcopenia is associated with an increased risk of mortality and poses a substantial health burden worldwide. Shenling Baizhu San (SLBZS) shows efficacy in this comorbidity, but how it exerts this effect remains unclear.